AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the promotion of Charles N. York to chief financial officer from vice president of finance and accounting. Mr. York has been with the company since its inception in 2013, serving first as a consultant before joining as a full-time employee in the summer of 2014. He has 16 years of financial expertise that includes acquisitions and divestitures, private equity transactions, and an initial public offering.
“Charles is a highly valued member of the team at Aeglea and this promotion reflects his strategic and operational impact on the company, including his role in closing our $44 million Series B financing earlier this year,” said David G. Lowe, Ph.D., co-founder, president and chief executive officer. “His experience and dedication will be key factors in helping Aeglea achieve our mission of developing treatments to address significant unmet medical needs for patients with inborn errors of metabolism and cancer.”
“The combination of an experienced team and a novel technology platform separates Aeglea from companies in the space,” said Mr. York. “I look forward to continuing our evolution as a clinical-stage company.”
Prior to joining Aeglea, Mr. York served as consulting chief financial officer at Bridgepoint Consulting, focusing on growth stage life science companies. He earned his bachelor’s degree in business administration and accounting from University of Connecticut and a Master of Business Administration degree from the Red McCombs School of Business at The University of Texas at Austin.
About Aeglea BioTherapeutics
Aeglea is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. Aeglea’s lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is expected to enter clinical trials in 2015 in cancer and 2016 in arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocysteine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.
For more information, visit http://aegleabio.com.